Tecentriq combo again meets PFS endpoint in Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy met the co-primary endpoint of improving progression-free survival (PFS) vs.

Read the full 269 word article

User Sign In